1 / 40

Myeloid Blastic Transformation of Myeloproliferative Neoplasms A Review of 112 Cases 

Myeloid Blastic Transformation of Myeloproliferative Neoplasms A Review of 112 Cases . Presenter: Syed Jawad Noor, PGY3 Mentor: Meir Wetzler June 09, 2010. Our Team. Syed J. Noor Wei Tan Gregory E. Wilding Laurie A. Ford Maurice Barcos Sheila N.J. Sait Annemarie W. Block

judith
Télécharger la présentation

Myeloid Blastic Transformation of Myeloproliferative Neoplasms A Review of 112 Cases 

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Myeloid Blastic Transformation of Myeloproliferative Neoplasms A Review of 112 Cases  Presenter: Syed Jawad Noor, PGY3 Mentor: Meir Wetzler June 09, 2010

  2. Our Team Syed J. Noor Wei Tan Gregory E. Wilding Laurie A. Ford Maurice Barcos Sheila N.J. Sait Annemarie W. Block James E. Thompson Eunice S. Wang Meir Wetzler

  3. Myeloproliferative Neoplasms (MPNs) Clonal hematologic diseases Excess production of ≥1 lineages of mature blood cells Predisposition to bleeding and thrombotic complications Extramedullary hemotopoiesis A variable progression to leukemia

  4. MPN Types Polycythemia Vera (PV) Essential Thrombocythemia (ET) Myelofibrosis (MF) Primary MF (PMF) Secondary MF (SMF)

  5. Polycythemia Vera (PV) An expansion in red blood cell production Essential Thrombocytosis (ET) An isolated elevation in platelet count

  6. Myelofibrosis (MF) Primary or secondary (post-PV or post-ET) • A fibrotic bone marrow and peripheral cytopenia • Higher risk of leukemic transformation

  7. JAK2 mutation in MPN L P P JAK2 JAK2 JAK2 JAK2 Signaling Signaling 95% in PV; 50-60% in ET and MF

  8. Myeloid Blastic Transformation of Myeloproliferative Neoplasms MPNs are known to transform into acute leukemia in approximately 4-6% of the patients ~50% of acute leukemia cases following JAK2-positive MPN continue to carry the mutation Pathogenesis of the blastic transformation in MPN remains unclear

  9. Known risk factors for Blastic Transformation Alkylating agents Radiation DNA damaging chemotherapy drugs

  10. Research Study Objectives • To gain more insight into the evolution & risk factors playing role in blastic transformation • Treatment outcome of patients developing blastic transformation from classic MPN

  11. Methods

  12. Patients • 89 cases from literature • 23 cases from RPCI • PV, ET, MF, SMF or MPN-U • Blast phase defined as persistent ≥20% marrow or peripheral blood blasts

  13. Contd… • Therapy • anthracycline (daunorubicin at 60 mg/m2) + cytosine arabinoside (100 mg/m2) chemotherapy in a “7+3” fashion

  14. Contd… • 3 pt had SCT in addition to chemotherapy • All other pts received supportive care only • Response was CR or CRi

  15. Statistical Analyses • Fisher’s exact test. • Wilcoxon rank sum test. • Kaplan-Meier method. • log-rank test. • SAS (version 9.1)

  16. Results • Both RPCI and literature pt. populations did not differ in • Age at diagnosis of MPN or blastic transformation, • Gender • Prior use of interferon • Karyotype aberrations • Overall survival of the two cohorts was similar and poor

  17. Comparison between RPCI dataset and other three datasets

  18. Diagnosis Differences Percent

  19. Time from MPN diagnosis to Blast phase Percent

  20. Less than 3 Therapies Percent

  21. Prior Hydroxyurea Therapy Percent

  22. Prior Alkylating Agents Percent

  23. Prior Erythropoietin Percent

  24. Normal Karyotype Percent

  25. Insignificant Variables of both Cohorts • Age @ MPN diagnosis • Age @ AML diagnosis • Gender • Prior use of Interferon • Karyotype aberrations

  26. Overall Survival

  27. Survival analysis for RPCI + other three data sets

  28. Survival By Diagnosis Months

  29. Age at MPN Diagnosis Age @ MPN <60 ≥60 P=0.0493

  30. Less than 3 Therapies <3 Therapies N Y P=0.0242

  31. Complex Karyotype Complex Karyotype N Y P=0.0104

  32. Non-significant variables • Time from MPN diagnosis to Blast phase • Age @ AML diagnosis • Gender • Prior Hydroxyurea • Prior Alkylating Agents • Prior Erythropoietin • Prior Interferon • Karyotype abnormalities other than Complex Kryotype

  33. Survival analysis for RPCI dataset

  34. P0.0031 P0.0119 P0.0009 P<0.0001 Median Survival in Months

  35. Discussion • Reasons for the heterogeneity -- Differing criteria for MPN diagnosis --Variety in the yield of karyotype analysis • Whether blastic transformation is a sequel of therapy, natural progression or a combination of the two continues

  36. Contd…. • Superior survival with allogeneic SCT • SCT should be considered before the disease progresses to the blastic phase

  37. Contd…. • Selective JAK1 and JAK2 inhibitor, INCB018424, has demonstrated some single agent activity in relapsed/refractory patients with leukemic transformation of Myelofibrosis

  38. Conclusion • Patients with <3 prior therapies & • Lack of complex karyotype have longer survival • Attempts for early identification of patients at risk for disease progression • Allogeneic SCT for the eligible patient • Searching for novel therapeutic agents, alone or in combination

More Related